A Study to Assess the Safety and Efficacy of Nitric Oxide Injection Into Unresectable Solid Primary or Metastatic Tumors
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05351502 |
Recruitment Status :
Recruiting
First Posted : April 28, 2022
Last Update Posted : April 2, 2024
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Cancer | Drug: Nitric Oxide 25,000 ppm Drug: Nitric Oxide 50,000 ppm Drug: Nitric Oxide 100,000 ppm Drug: Nitric Oxide selected dose | Phase 1 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 38 participants |
Allocation: | Non-Randomized |
Intervention Model: | Sequential Assignment |
Intervention Model Description: | In Part A, the following gNO doses will be studied to determine MTD and/or OBD: 25,000 ppm, 50,000 ppm and 100,000 ppm. Additional dose levels may be evaluated based on the emerging data as determined by the Safety Review Committee. Once the MTD and/or OBD is determined, additional patients will be treated in Part B Dose Expansion to further characterize the safety and biomarkers of gNO and determine RP2D. |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Phase 1, Open-Label, Dose Escalation and Dose Expansion Study to Assess the Safety and Efficacy of Nitric Oxide Injection Into Unresectable Solid Cutaneous/Subcutaneous Primary or Metastatic Tumors |
Actual Study Start Date : | August 14, 2022 |
Estimated Primary Completion Date : | July 1, 2024 |
Estimated Study Completion Date : | April 1, 2025 |
Arm | Intervention/treatment |
---|---|
Experimental: Cohort 1
Subjects will receive 25,000 ppm NO
|
Drug: Nitric Oxide 25,000 ppm
Intratumoral injection of 25,000 gNO
Other Name: gNO injection |
Experimental: Cohort 2
Subjects will receive 50,000 ppm NO
|
Drug: Nitric Oxide 50,000 ppm
Intratumoral injection of 50000 gNO |
Experimental: Cohort 3
Subjects will receive 100,000 ppm NO
|
Drug: Nitric Oxide 100,000 ppm
Intratumoral injection of 100,000 gNO |
Experimental: RP2D Expansion
Subjects will receive the RP2D dose of NO
|
Drug: Nitric Oxide selected dose
Intratumoral injection of selected does on gNO |
- Incidence of AEs, SAEs and DLTs (safety) parameters. [ Time Frame: up to12 weeks from injection ]The incidence and characteristics of adverse events (AEs), serious adverse events (SAEs), dose-limiting toxicities (DLTs) and changes in assessed safety parameters. Toxicity will be graded according to NCI CTCAE version 5.0
- Anti-tumor activity of a single intratumoral gNO injection at all administered doses [ Time Frame: up to Day 21 from injection ]The anti-tumor activity of a single intratumoral gNO injection will be measured per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, and secondarily immune-related RECIST (iRECIST).
- Assessment of predictive biomarkers for anti-tumor activity of a single intratumoral gNO injection [ Time Frame: up to Day 21 from injection ]Measurement of blood immune biomarkers levels
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patient (male or female) is at least 18 years of age at the time of signature of the informed consent form.
- Patient has an ECOG Performance Status score of 0-3 and with a life expectancy of ≥3 months.
- Patient must have a confirmed diagnosis of at least one unresectable cutaneous or subcutaneous histologically confirmed primary or metastatic solid tumor. Up to five target lesions may be identified.
- No therapy of proven efficacy exists for the tumor, the tumor is not amenable to standard therapies, the tumor has failed to respond to standard therapy or has progressed despite standard therapy.
- Patient has measurable disease on imaging based on RECIST Version 1.1.
- Patient have adequate hematologic and organ function.
- Patient have not had radiotherapy to the targeted lesions within the preceding 12 months.
- Superficial tumor axis minimum length and depth of 4.5mm. .
- Patient is not with childbearing potential or agrees to use adequate contraceptive methods
Exclusion Criteria:
- The tumor is situated in the lymph node, in thyroid, close to trachea or in facial area or other region which, in the Investigator's opinion, can pose extra risk to the patient.
- Has received prior systemic anti-cancer therapy including investigational agents within 14 days of the start of study treatment.
- Active central nervous system tumors or metastases..
- Received systemic corticosteroid therapy ≤1 week prior to study treatment or any other form of systemic immunosuppressive medication for medically significant acute or chronic conditions.
- Any unresolved toxicity NCI CTCAE Grade ≥2 from previous anticancer therapy with the exception of alopecia, vitiligo, neuropathy and protocol-defined laboratory values.
- Active or prior documented autoimmune or inflammatory disorders.
- History of primary immunodeficiency, history of allogenic organ transplant that requires therapeutic immunosuppression and the use of immunosuppressive agents within 28 days of enrolment.
- Known active infection and uncontrolled intercurrent illness.
- Receiving drugs that have contraindication with NO.
- Patient is receiving anticoagulants including low molecular weight heparin.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05351502
Contact: Edith Dekel | 972-50-8464449 | edekel@beyondcancer.com | |
Contact: Yaara Ber, PhD | yber@beyondcancer.com |
Israel | |
Soroka Medical Center | Recruiting |
Be'er Sheva, Israel | |
Hadassah Ein-Karem | Recruiting |
Jerusalem, Israel | |
Sheba Medical Center | Recruiting |
Ramat Ef'al, Israel | |
Sourasky Tel Aviv Medical Center | Recruiting |
Tel Aviv, Israel |
Study Director: | David Greenberg, MD | Study Internal Medical Monitor |
Responsible Party: | Beyond Air Inc. |
ClinicalTrials.gov Identifier: | NCT05351502 |
Other Study ID Numbers: |
BA-ONC-01 |
First Posted: | April 28, 2022 Key Record Dates |
Last Update Posted: | April 2, 2024 |
Last Verified: | April 2023 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Product Manufactured in and Exported from the U.S.: | No |
Intratumoral Injection Nitric Oxide single gNO injection |
Neoplasm Metastasis Neoplastic Processes Neoplasms Pathologic Processes Nitric Oxide Bronchodilator Agents Autonomic Agents Peripheral Nervous System Agents Physiological Effects of Drugs Anti-Asthmatic Agents |
Respiratory System Agents Free Radical Scavengers Antioxidants Molecular Mechanisms of Pharmacological Action Neurotransmitter Agents Endothelium-Dependent Relaxing Factors Vasodilator Agents Gasotransmitters Protective Agents |